Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631966 | 0.98 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL12631948 | 0.98 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL1870673 | 0.80 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL12632007 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL3603986 | 0.79 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL3595027 | 0.79 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL12631967 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL12631952 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL14996293 | 0.77 | SHBG (0.44) | SLC6A2SLC6A4SLC6A3TP53KDM4E | |
| SCHEMBL1863892 | 0.73 | SLC6A4 (0.35) | SLC6A2SLC6A4SLC6A3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | SLC6A2 3389/4885SLC6A4 3809/4885SLC6A3 2752/4885 |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | SLC6A2 3389/4885SLC6A4 3809/4885SLC6A3 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.